| EN

SIMCERE PHARMA (HK.2096) to Host 2022 R&D Day

Release time:2022-04-07

SIMCERE PHARMA (HK.2096), an innovation and R&D-driven pharmaceutical company with a mission of “providing today’s patients with medicines of the future”, will host a virtual R&D Day, on Friday, 15 April, 2022, at 21:00-23:00 (HKT) / 9:00-11:00 (EST) / 13:00-15:00 (GMT).

2022 R&D 2.jpg

The R&D Day will feature presentations from Mr. Ren Jinsheng(Chairman of the Board &CEO), Mr. Zhou Gaobo(CIO), Dr. Tang Renhong(EVP), Dr. Bijoyesh Mookerjee(CMO), Dr. Danny Chen(SVP) and Dr. Kevin Oliver(SVP).


21:00 – 21:05 Welcome by Mr. Ren Jinsheng (Chairman of the Board & CEO)

21:05 – 21:25 Company Overview & Strategy by Mr. Zhou Gaobo (CIO)

21:25 – 21:45 Pre-clinical R&D update by Dr. Tang Renhong (EVP)

21:45 – 22:05 Late-Stage Oncology Pipeline by Dr. Bijoyesh Mookerjee (CMO)

22:05 – 22:25 Late-Stage Non-oncology Pipeline by Dr. Danny Chen (SVP)

22:25 – 22:40 BD Collaboration by Dr. Kevin Oliver (SVP)

22:40 – 23:00 Q&A Hosted by Mr. Jason Bao (Secretary of the Board)


To register for the event, please click here (https://www.simcere.com/xs2022/).

For further information, please contact:

Jason Bao, The Secretary of the Board
E-mail: ir@simcere.com 

About Simcere

Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future.” Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.